Lloyd Alcera, MD
Psychiatry · Marlton, NJNPI 1184854259
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $158,635 of the $186,890 with a category attached, or 84.9%. Otsuka America Pharmaceutical, Inc. accounts for 81.8% of it on its own, with 20 other manufacturers making up the rest. Among psychiatry clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 501 payments — averaging $373.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$153K
- E.r. Squibb & Sons, L.L.C.$25K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$5K
- Neurocrine Biosciences, Inc.$607
- Teva Pharmaceuticals USA, Inc.$542
- Sunovion Pharmaceuticals Inc.$466
- plus $2K from 15 others
What the payments were for
- Speaking & faculty fees$158,63585%
- Travel & lodging$16,4809%
- Food & beverage$11,5596%
- Education$2160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 224 | $152,817 |
| E.r. Squibb & Sons, L.L.C. | 39 | $25,397 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 8 | $4,572 |
| Neurocrine Biosciences, Inc. | 25 | $607 |
| Teva Pharmaceuticals USA, Inc. | 29 | $542 |
| Sunovion Pharmaceuticals Inc. | 41 | $466 |
| AbbVie(2 entities) | 25 | $410 |
| Lundbeck LLC | 20 | $365 |
| Johnson & Johnson | 15 | $331 |
| Alkermes, Inc. | 16 | $313 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $297 |
| Corium, LLC | 9 | $238 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $193 |
| Ironshore Pharmaceuticals Inc. | 4 | $67 |
| Indivior Inc. | 3 | $59 |
| Avanir Pharmaceuticals, Inc. | 4 | $59 |
| Idorsia Pharmaceuticals US Inc | 4 | $59 |
| Shire North American Group Inc | 3 | $43 |
| Vanda Pharmaceuticals Inc. | 2 | $27 |
| Neos Therapeutics, LP | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$109,444
- ABILIFY MAINTENA$44,041
- COBENFY$23,998
- ABILIFY ASIMTUFII$2,670
- INGREZZA$133
- Azstarys$125
- VRAYLAR$125
How this compares
$186,890 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 26 | $62,302 |
| VraylarCariprazine Hcl | 15 | $35,813 |
| RexultiBrexpiprazole | 22 | $31,396 |
| VyvanseLisdexamfetamine Dimesylate | 36 | $15,238 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 34 | $6,217 |
| CymbaltaDuloxetine Hcl | 11 | $6,119 |
| Lisdexamfetamine Dimesylate | 23 | $5,846 |
| TrintellixVortioxetine Hydrobromide | 11 | $4,955 |
| Lurasidone Hcl | 24 | $4,745 |
| AzstarysSerdexmethylphen/Dexmethylphen | 11 | $4,532 |
| Vilazodone Hcl | 32 | $4,131 |
| Paliperidone ErPaliperidone | 18 | $3,508 |
| Trazodone Hcl | 67 | $2,898 |
| Quetiapine Fumarate | 142 | $2,665 |
| Aripiprazole | 44 | $2,008 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $331 | $62,30226 claims |
| AbbVieVraylar | $410 | $35,81315 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $152,817 | $31,39622 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $193 | $20,19447 claims |
| Corium, LLCAzstarys | $238 | $4,53211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Other psychiatry in Marlton
- Marc CantillonLivingston$522K
- Robert BransfieldRed Bank$415K
- Erika ConcepcionLong Branch$354K
- Leon RosenbergCherry Hill$257K
- Gary SmallHackensack$170K
- Shankar SrinivasanParsippany$155K
- Matthew PiteraToms River$153K
- Boris BorodulinEast Brunswick$116K
- Anthony RostainCamden$110K
- Aijaz NanjianiParamus$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.